The Food and Drug Administration last week updated 2017 draft guidance to clarify the categories of clinical and decision support software subject to FDA oversight under the 21st Century Cures Act based on risk, and released final guidance on the types of software no longer considered medical devices under the Act’s amended definition of device. “We’re making clear that certain digital health technologies — such as mobile apps that are intended only for maintaining or encouraging a healthy lifestyle — generally fall outside the scope of the FDA’s regulation,” said Principal Deputy Commissioner Abernethy, M.D. “Such technologies tend to pose a low risk to patients, but can provide great value to consumers and the health care system.”

Related News Articles

Headline
Kansas Gov. Laura Kelly has reached agreement with Senate Republicans on a bipartisan proposal to expand Medicaid eligibility to low-income uninsured…
Headline
The Centers for Medicare & Medicaid Services has delayed 2020 private payer data reporting for the Clinical Diagnostic Test Payment System until 2021 for…
Headline
The Senate today voted 71-23 to pass legislation (H.R. 1865) funding the Department of Health and Human Services and other non-Defense agencies for fiscal…
Headline
The House today approved a $1.4 trillion spending package for fiscal year 2020. The bills include a number of key issues for hospitals and health systems…
Headline
The Food and Drug Administration Friday cleared for marketing in the U.S. the first fully disposable duodenoscope. The EXALT Model D Single-Use Duodenoscope is…
Headline
Leaders of the House and Senate Appropriations committees have reached an agreement in principle on fiscal year 2020 funding, with the House expected to vote…